Piramal's Neuraceq receives FDA approval for amyloid imaging

03/20/2014 | HealthImaging.com

Piramal Imaging's diagnostic amyloid PET agent F-18 florbetaben, branded as Neuraceq, has been approved by the FDA. Neuraceq is indicated for PET imaging of the brain to estimate beta amyloid plaque density in patients with cognitive impairment who are being evaluated for possible Alzheimer's disease. Piramal Imaging has partnered with IBA Molecular for manufacturing and distribution of Neuraceq.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC